© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Retina
Telemedicine ushers in new chapter in eye care
May 10, 2021
Worldwide increase in technologies for ophthalmic use is dramatic.
Analyzing 24-month data of the PALADIN study
May 07, 2021
Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).
Should nonclinicians inject dexamethasone implants?
May 07, 2021
Studies on nurse-led services find a low level of complications among patients.
X-linked retinitis pigmentosa Phase 1/2 clinical trial provides positive 12-month data
May 06, 2021
According to Applied Genetic Technologies Corp., groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials.
Looking at real-world trial data replication outcomes of IRIS Registry data
May 06, 2021
Theodore Leng, MD, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.
Linking patient imaging data to AAO IRIS Registry
May 06, 2021
Michael Mbagwu, MD, speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.
Clinical results study dexamethasone implant effect on macular thickness
May 05, 2021
Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
Targeting neurodegenerative diseases with risuteganib
May 03, 2021
Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.
Investigating the low vulnerability of posterior eye segment to SARS-CoV-2
May 02, 2021
Steffen E. Künzel, MD, discusses the key points of his research presentation regarding low vulnerability of the posterior eye segment to SARS-CoV-2 infection.
Study outlines use of intravitreal injection of allogeneic human retinal progenitor cells to treat RP
May 02, 2021
During ARVO 2021, Sunil Srivastava, MD, points out that optical coherence tomography characteristics may be predictive of the efficacy of the injections.